194 related articles for article (PubMed ID: 16890599)
21. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases.
Alavian SM; Tabatabaei SV; Keshvari M; Behnava B; Miri SM; Elizee PK; Lankarani KB
Liver Int; 2010 Sep; 30(8):1173-80. PubMed ID: 20629950
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
23. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
BMC Infect Dis; 2012 Nov; 12():324. PubMed ID: 23181537
[TBL] [Abstract][Full Text] [Related]
24. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
25. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
Reddy KR; Shiffman ML; Morgan TR; Zeuzem S; Hadziyannis S; Hamzeh FM; Wright TL; Fried M
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):124-9. PubMed ID: 17196435
[TBL] [Abstract][Full Text] [Related]
26. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
27. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Ferenci P; Brunner H; Laferl H; Scherzer TM; Maieron A; Strasser M; Fischer G; Hofer H; Bischof M; Stauber R; Gschwantler M; Steindl-Munda P; Staufer K; Löschenberger K;
Hepatology; 2008 Jun; 47(6):1816-23. PubMed ID: 18454510
[TBL] [Abstract][Full Text] [Related]
28. [Individualized respond guidance treatment of chronic hepatitis C with combination of peginterferon α-2a and ribavirin].
Chen WL; Chen XP; Chen XF; Huang J; Luo XD
Zhonghua Gan Zang Bing Za Zhi; 2010 Aug; 18(8):585-9. PubMed ID: 20825712
[TBL] [Abstract][Full Text] [Related]
29. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.
Zeuzem S; Hultcrantz R; Bourliere M; Goeser T; Marcellin P; Sanchez-Tapias J; Sarrazin C; Harvey J; Brass C; Albrecht J
J Hepatol; 2004 Jun; 40(6):993-9. PubMed ID: 15158341
[TBL] [Abstract][Full Text] [Related]
30. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
Mangia A; Minerva N; Bacca D; Cozzolongo R; Ricci GL; Carretta V; Vinelli F; Scotto G; Montalto G; Romano M; Cristofaro G; Mottola L; Spirito F; Andriulli A
Hepatology; 2008 Jan; 47(1):43-50. PubMed ID: 18069698
[TBL] [Abstract][Full Text] [Related]
31. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
32. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Jensen DM; Morgan TR; Marcellin P; Pockros PJ; Reddy KR; Hadziyannis SJ; Ferenci P; Ackrill AM; Willems B
Hepatology; 2006 May; 43(5):954-60. PubMed ID: 16628671
[TBL] [Abstract][Full Text] [Related]
33. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
[TBL] [Abstract][Full Text] [Related]
34. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
Gerotto M; Dal Pero F; Bortoletto G; Ferrari A; Pistis R; Sebastiani G; Fagiuoli S; Realdon S; Alberti A
J Hepatol; 2006 Jan; 44(1):83-7. PubMed ID: 16271794
[TBL] [Abstract][Full Text] [Related]
36. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.
Moreno C; Deltenre P; Pawlotsky JM; Henrion J; Adler M; Mathurin P
J Hepatol; 2010 Jan; 52(1):25-31. PubMed ID: 19931204
[TBL] [Abstract][Full Text] [Related]
37. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
Kamal SM; Fouly AE; Kamel RR; Hockenjos B; Al Tawil A; Khalifa KE; He Q; Koziel MJ; El Naggar KM; Rasenack J; Afdhal NH
Gastroenterology; 2006 Mar; 130(3):632-8. PubMed ID: 16530503
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation.
Gordon FD; Kwo P; Ghalib R; Crippin J; Vargas HE; Brown KA; Schiano T; Chaudhri E; Pedicone LD; Brown RS
J Clin Gastroenterol; 2012 Sep; 46(8):700-8. PubMed ID: 22739223
[TBL] [Abstract][Full Text] [Related]
39. Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.
Balart LA; Lisker-Melman M; Hamzeh FM; Kwok A; Lentz E; Rodriguez-Torres M;
Am J Gastroenterol; 2010 Oct; 105(10):2177-85. PubMed ID: 20389293
[TBL] [Abstract][Full Text] [Related]
40. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
